Solid Tumors
📧 Sign up to get email alerts when something new happens for Solid Tumors.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-09-29Clinical Trial Update: Retun-to-school Adaptation Program for Children With Cancer [NA]
Clinical trial update indicating the completion of a return-to-school adaptation program study for children with cancer, sponsored by Gazi U…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies [Phase 1, Phase 2]
A Phase 1/2 clinical trial update describes BL-B01D1 in patients with multiple solid tumors, including recurrent or metastatic gynecologic m…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors [Phase 1]
A Phase I clinical trial evaluating BL-M07D1 for locally advanced or metastatic digestive tract tumors and other solid tumors is currently r…
-
CLINICAL_TRIALS trial_result · 2025-09-26Clinical Trial Update: A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors [Phase 1]
A Phase 1 clinical trial update indicating BL-M02D1 for locally advanced or metastatic digestive tract tumors and other solid tumors is curr…
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: A First-in-Human Study of PRL3-ZUMAB [Phase 1]
Phase 1 first-in-human study evaluating PRL3-ZUMAB in patients with advanced solid tumors. The trial is currently active and not recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-09-25Clinical Trial Update: A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors [Phase 1, Phase 2]
The LB101 study in participants with advanced solid tumors (Phase 1/2) was terminated.
-
CLINICAL_TRIALS trial_result · 2025-09-25Clinical Trial Update: A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours [Phase 1, Phase 2]
Phase I/II study evaluating LM-2417 in adults with advanced solid tumors, currently recruiting.
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2a study of IPG7236 in patients with solid tumors is currently recruiting. The trial will assess safety, tolerability, and pharmacok…
-
CLINICAL_TRIALS trial_result · 2025-09-24Clinical Trial Update: To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550 [Phase 1]
A Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of INCB086550 in patients with solid tumors; the trial status is t…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors [Phase 1, Phase 2]
A clinical trial update for LCB84, a TROP2-targeting antibody-drug conjugate, evaluating it as a single agent and in combination with an ant…
-
CLINICAL_TRIALS other · 2025-09-24Clinical Trial Update: RVU120 Rollover Study [Phase 2]
A Phase 2 rollover study of RVU120 in advanced solid tumors, acute myeloid leukemia, and high-risk myelodysplastic syndrome is not yet recru…
-
CLINICAL_TRIALS trial_result · 2025-09-23Clinical Trial Update: Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery [Phase 1]
Phase 1 trial evaluating the combination of nivolumab and ipilimumab in adults with HIV-associated relapsed or refractory classical Hodgkin …
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors [Phase 1]
Phase 1 study evaluating flavored oral irinotecan VAL-413 (Orotecan) with temozolomide for recurrent pediatric solid tumors is currently rec…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN [Phase 2]
Phase 2 clinical trial evaluating Efbemalenograstim Alfa for primary and secondary prevention of febrile neutropenia in patients with solid …
-
CLINICAL_TRIALS trial_result · 2025-09-23Clinical Trial Update: Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors [Phase 1, Phase 2]
This clinical trial update describes a trastuzumab-based CAR-T therapy targeting HER2-positive advanced breast cancer and other solid tumors…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI [Phase 1, Phase 2]
A Phase 1/2 clinical trial update evaluating azacitidine in combination with QPOP and CURATE.AI for solid tumors is currently recruiting, co…
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors. [NA]
A clinical trial evaluating the combination of hV01 oncolytic vaccinia virus and a PD-1 inhibitor in advanced solid tumors, currently recrui…
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer [Phase 1]
First-in-human Phase 1 study of RLY-2608, a mutant-selective PI3Kα inhibitor, in adults with advanced solid tumors. The trial also evaluates…
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation [Phase 1, Phase 2]
This clinical trial update covers the Phase 1/2 study of HRS-4642 in patients with advanced KRAS G12D-mutant solid tumors. The trial is curr…
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: N-Acetylcysteine Roles in Preserving Renal Function Measured by Urinary KIM-1 (Kidney Injury Molecule-1) and Serum Creatinine on Cancer Patients With Cisplatin Based Chemotherapy: A Randomized Placebo-Controlled Trial [Phase 2, Phase 3]
A randomized, placebo-controlled trial is planned to evaluate whether N-Acetylcysteine can preserve renal function in cancer patients receiv…
-
CLINICAL_TRIALS trial_result · 2025-09-18Clinical Trial Update: Study of SUPLEXA in Patients With Metastatic Solid Tumours and Haematologic Malignancies [Phase 1]
Phase 1 study of SUPLEXA in patients with metastatic solid tumors and hematologic malignancies has completed with results posted.
-
CLINICAL_TRIALS research · 2025-09-18Clinical Trial Update: A Study of MHB046C Injection in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
Clinical trial update for MHB046C Injection in patients with advanced solid tumors, currently recruiting for Phase 1/2.
-
CLINICAL_TRIALS trial_result · 2025-09-16Clinical Trial Update: A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors [Phase 1]
Phase 1 study of KD033 (SAR445710) in metastatic or locally advanced solid tumors has been terminated; the document provides trial details i…
-
CLINICAL_TRIALS research · 2025-09-12Clinical Trial Update: A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
This clinical trial update reports a Phase 1/2 study of YL202 in combination with other anti-tumor therapies for patients with advanced soli…
-
CLINICAL_TRIALS research · 2025-09-12Clinical Trial Update: Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors [Phase 2]
Phase II study of tunlametinib in NRAS-mutant non-melanoma refractory solid tumors is currently recruiting.